LifewardLFWD +0.78%56 Debt-to-EBITDA is -0.46 as of Mar. 2026. GuruFocus rates LFWD with a GF Score™ of 56/100 and a GF Value™ of $13.78 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Lifeward ranks worse than 212765.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Lifeward's Debt-to-EBITDA or its related term are showing as below:
LFWD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.71 Med: -0.2 Max: -0.05
Current: -0.53
During the past 13 years, the highest Debt-to-EBITDA Ratio of Lifeward was -0.05. The lowest was -0.71. And the median was -0.20.
LFWD's Debt-to-EBITDA is ranked worse than 100% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs LFWD: -0.53
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Lifeward Debt-to-EBITDA Related Terms
Lifeward Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Lifeward's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFWD vs ICCM, IRIX, GTHP: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Lifeward's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifeward Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lifeward's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lifeward's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Lifeward (LFWD) has a Debt-to-EBITDA of -0.46 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lifeward. According to the industry distribution chart, Lifeward ranks #999999 out of 470 companies in the Medical Devices & Instruments industry.
Is Lifeward's Debt-to-EBITDA too high?
Lifeward's current Debt-to-EBITDA is -0.46. Based on the distribution chart, Lifeward ranks #999999 out of 470 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lifeward has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifeward's Debt-to-EBITDA compare to ICCM and IRIX?
According to the Medical Devices & Instruments industry distribution chart, Lifeward ranks #999999 out of 470 companies for Debt-to-EBITDA. This places Lifeward in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lifeward. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifeward's current Debt-to-EBITDA is -0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifeward stock overvalued right now?
Based on GuruFocus' analysis, Lifeward (LFWD) is currently considered Possible Value Trap. The stock's GF Value™ is $13.78, compared to a current price of $8.39 — trading 39.2% below its estimated fair value. The current Debt-to-EBITDA is -0.46. Lifeward's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Lifeward (LFWD), the current Debt-to-EBITDA is -0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifeward (LFWD) Overvalued in 2026?
Based on GuruFocus' analysis, Lifeward stock appears to be undervalued.
The current stock price of $8.39 is trading 39.2% below its estimated GF Value™ of $13.78.
GuruFocus considers Lifeward to be Possible Value Trap.
Key valuation signals for LFWD:
Debt-to-EBITDA: -0.46
GF Value™: $13.78 vs. price of $8.39 (39.2% below fair value)
No single metric tells the full story. See the LFWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings include the ReWalk Personal Exoskeleton, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. The company operates in the United States, which generates the majority of its revenue, as well as in Europe, Germany, Asia Pacific, and the rest of the world.
56GF Score
Get the complete analysis for LFWD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFWD has been successfully added to your 
